FMP
PainReform Ltd.
PRFX
NASDAQ
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
0.81 USD
-0.0199 (-2.46%)
About
ceo
Mr. Ilan Hadar M.B.A.
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
https://www.painreform.com
exchange
NASDAQ
Description
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.
CIK
0001801834
ISIN
IL0011651580
CUSIP
M77798102
Address
65 Yigal Alon Street
Phone
972 3 717 7050
Country
IL
Employee
7
IPO Date
Sep 1, 2020
Key Executives
